The authors reported a patient with a large prolactinoma (PRL 1,716 ng/ml) who was treated with bromocriptine for two years and followed up for a subsequent 36 months. After the start of the therapy, the tumor size was dramatically reduced, and finally the disappearance of the tumor was confirmed by high resolution coronal CT. The serum prolactin level and pituitary function were normalized. Th...

Background: CyclosetTM is a quick-release formulation of bromocriptine mesylate, a dopamine agonist, which in animal models of insulin resistance and type 2 diabetes acts centrally to reduce resistance to insulinmediated suppression of hepatic glucose output and tissue glucose disposal. In such animals, bromocriptine also reduces hepatic triglyceride synthesis and free fatty acid mobilization, ...

BACKGROUND Patients with intellectual disabilities may be treated with antipsychotic medications for a variety of diagnoses. Use of this category of medication can increase prolactin levels and place the patient at risk for sexual dysfunction and lower bone mineral density. The proposed mechanism of action is affinity for the dopamine receptor. Use of bromocriptine, a dopamine receptor antagoni...

The role of dopamine in behavioural arousal and the frequent occurrence of dementia in patients with Parkinson's disease provide the rationale for the use of these substances in dementia, although dopamine levels in the caudate nucleus and substantia nigra are not depressed in primary degenerative dementia (PDD)56. L-Dopa has yielded contradictory results.6 Half of the trials reported an improv...

Introduction and Aim: Genetic epigenetic factors affect chronic myeloid leukemia (CML) treatment response. This study aimed to investigate HOXA5 methylation gene expression with Imatinib mesylate (IM) response in CML patients assess their predictive value as markers. Materials Methods: Blood samples were collected from 50 (25 responders 25 non-responders mesylate) healthy controls of the same a...

Genetic and pharmacological studies suggest an important role of the dopamine D2 receptor (DRD2) in flexible behavioral adaptation, mostly shown in reward-based learning paradigms. Recent evidence from imaging genetics indicates that also intentional cognitive flexibility, associated with lateral frontal cortex, is affected by variations in DRD2 signaling. In the present functional magnetic res...

The long term effects of a de novo treatment with levodopa versus bromocriptine were compared in respectively 13 and 15 previously untreated patients with Parkinson's disease in a prospective randomised trial. Thirteen patients were treated with levodopa alone (mean dose 444, SEM 63 mg daily) whereas 15 others received bromocriptine alone (mean dose 50, SEM 6 mg daily) during 37, SEM 4 and 32, ...

Thyrotropine secretion in human beings is under the influence of various factors. The effect of the hormones, triiodothyronine, thyroxine, somatostatin and thyroid-stimulating hormone has been well known. In this study the direct effect of stimulation of the dopaminergic system by bromocriptine on the thyrotropine secretion was investigated. In this study twenty women with hyperprolactinemia r...

The role of dopamine in behavioural arousal and the frequent occurrence of dementia in patients with Parkinson's disease provide the rationale for the use of these substances in dementia, although dopamine levels in the caudate nucleus and substantia nigra are not depressed in primary degenerative dementia (PDD)56. L-Dopa has yielded contradictory results.6 Half of the trials reported an improv...